Answers are grounded in this paper and cite their sources.
Analysis interprets cost-effectiveness of diabetes remission programs, suggesting important economic considerations.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Stjepan Škudar (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: